Cargando…
Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
People with cystic fibrosis (pwCF) were considered to be clinically vulnerable to COVID-19 and were therefore given priority in the vaccination campaign. Vaccines induced a humoral response in these patients that was comparable to the response observed among the general population. However, the role...
Autores principales: | Alicandro, G., Orena, B.S., Rosazza, C., Cariani, L., Russo, M., Zatelli, M., Badolato, R., Gramegna, A., Blasi, F., Daccò, V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201328/ https://www.ncbi.nlm.nih.gov/pubmed/37263872 http://dx.doi.org/10.1016/j.vaccine.2023.05.041 |
Ejemplares similares
-
532 Humoral and cell-mediated responses to BNT162b2 mRNA vaccine against SARS-CoV-2 in people with cystic fibrosis
por: Daccò, V., et al.
Publicado: (2022) -
ePS4.06 Antibody response to administration of 2 doses of the BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
por: Alicandro, G., et al.
Publicado: (2022) -
Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies
por: Alicandro, Gianfranco, et al.
Publicado: (2022) -
SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy
por: Alicandro, Gianfranco, et al.
Publicado: (2022) -
Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over
por: Alicandro, Gianfranco, et al.
Publicado: (2022)